Buy this domain?
Click Here

April 2019
M T W T F S S
     
1234567
891011121314
15161718192021
22232425262728
2930  

Search

ato.my
Alemtuzumab
Alemtuzumab is a drug used in the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL) and T-cell lymphoma under the trade
Humanized antibody
synthesis of linear DNA fragments based on the reading of CDR sequences. Alemtuzumab is an early example of an antibody whose humanization did not include
CD52
associated with certain types of lymphoma. It is the protein targeted by alemtuzumab, a monoclonal antibody used for the treatment of chronic lymphocytic
Monoclonal antibody
Fc region. MAbs approved by the FDA (for cancer) as of 2005 include: Alemtuzumab Bevacizumab Cetuximab Gemtuzumab ozogamicin Ipilimumab Ofatumumab Panitumumab
Cladribine
be a highly effective immune reconstitution therapy in MS. Similar to alemtuzumab, cladribine is given as two courses approximately one year apart. Each
Cancer immunotherapy
which can lead to cell death. Approved immunotherapy antibodies include alemtuzumab, ipilimumab, nivolumab, ofatumumab, pembrolizumab and rituximab. Active
Management of multiple sclerosis
interferons beta-1a and beta-1b, four monoclonal antibodies: natalizumab, alemtuzumab, daclizumab and ocrelizumab, and five immunomodulators: glatiramer acetate
Leukemia
doxorubicin, prednisone, etoposide, cyclophosphamide, bleomycin VAPEC-B). Alemtuzumab (Campath), a monoclonal antibody that attacks white blood cells, has
Multiple sclerosis
mitoxantrone, natalizumab, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, and ocrelizumab. Their cost effectiveness as of 2012 is unclear. In
Anti-NMDA receptor encephalitis
useful when other therapies have failed. Other medications, such as alemtuzumab, remain experimental. The recovery process from anti-NMDAR encephalitis